Uncategorized
Santen files investigational new drug application for DE-122 for wet AMD treatment
Santen Pharmaceutical has filed an investigational new drug application with the FDA to begin clinical studies of DE-122 in patients with wet age-related macular degeneration, according to a press release from Tracon Pharmaceuticals. DE-122 is the ophthalmic formulation of TRC105, Tracon’s anti-endoglin antibody. Santen licensed the global rights from Tracon for the development of TRC105 in March 2014. Under the terms of the agreement, the filing will trigger a $3 million milestone payment to Tracon, the release said.